Crinetics Pharmaceuticals, Inc. (CRNX)
Valuation Overview•Is Crinetics Pharmaceuticals, Inc. Overvalued or Undervalued?
Market price has outpaced base-case intrinsic cash flows, pricing in significant future growth optimism.
Underlying fundamental quality and solvency metrics are in stable range.
Wall Street forecasts a balanced outlook with consensus price targets near the current price.
Confirm your valuation thesis with live pattern overlays, key pivot levels, and AI trade plans.
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q3'26Latest | $-1.18 | $-1.14 | +3.4% | ||
| Q2'26 | $-1.22 | $-1.23 | -0.8% | ||
| Q1'26 | $-1.37 | $-1.29 | +5.8% | ||
| Q4'25 | $-1.27 | $-1.38 | -8.7% | ||
| Q3'25 | $-1.13 | $-1.23 | -8.8% | ||
| Q2'25 | $-0.99 | $-1.04 | -5.1% | ||
| Q1'25 | $-0.92 | $-0.88 | +4.3% | ||
| Q4'24 | $-0.91 | $-0.96 | -5.4% |
The S&P 500 is at 22.8x trailing P/E — Fair relative to historical averages.
Quick answers to common questions about Crinetics Pharmaceuticals, Inc. (CRNX) valuation, health, and returns.
Crinetics Pharmaceuticals, Inc. is estimated to be overvalued under our discounted cash flow framework. overvalued (implying -29.3% downside from DCF intrinsic value of $60.07)
Crinetics Pharmaceuticals, Inc. has multiple valuation anchors: DCF Intrinsic Value: $60.07. A convergence of these signals offers higher conviction.
Crinetics Pharmaceuticals, Inc. displays n/a financial health with a composite quality score of N/A/100, supported by a .
Crinetics Pharmaceuticals, Inc. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Crinetics Pharmaceuticals, Inc.'s current growth trajectory is Stable. The company achieved N/A 1Y revenue growth and N/A 1Y EPS growth, compared to its 3Y revenue CAGR of N/A.
Wall Street consensus is Hold based on 0 analysts. The consensus price target represents a N/A change from current levels.
No major financial distress warning signs or extreme volatility triggers are flagged at this time.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.